Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00767871|
Recruitment Status : Completed
First Posted : October 7, 2008
Last Update Posted : July 25, 2011
Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network.
The specific aim of this study is to test the following hypotheses using 18F-FDG positron emission tomography (PET)
- Patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects.
- Patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram.
- The changes of fear work after the treatment will be associated with psychological variables and neurohormones.
|Condition or disease||Intervention/treatment||Phase|
|Panic Disorder||Drug: Lexapro||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||December 2008|
escitalopram (10-20mg) to panic patients
12 week treatment with lexapro
- 18FDG-PET, PDSS & HAM-A [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767871
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of, 135-710|
|Principal Investigator:||Bum-Hee Yu, M.D., Ph.D.||Samsung Medical Center|